Kim, Il-Kyu http://orcid.org/0000-0002-4661-0133
Diamond, Mark S.
Yuan, Salina
Kemp, Samantha B.
Kahn, Benjamin M.
Li, Qinglan
Lin, Jeffrey H. http://orcid.org/0000-0002-2518-6863
Li, Jinyang
Norgard, Robert J.
Thomas, Stacy K. http://orcid.org/0000-0002-6703-5246
Merolle, Maria
Katsuda, Takeshi http://orcid.org/0000-0003-3960-033X
Tobias, John W. http://orcid.org/0000-0002-5362-7013
Baslan, Timour
Politi, Katerina
Vonderheide, Robert H. http://orcid.org/0000-0002-7252-954X
Stanger, Ben Z. http://orcid.org/0000-0003-0410-4037
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (CA229803, CA076931, CA241084)
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
Article History
Received: 26 May 2023
Accepted: 12 February 2024
First Online: 20 February 2024
Competing interests
: Dr. Stanger receives research funding from Boehringer-Ingelheim and Revolution Medicines and previously served as a consultant to iTeos Therapeutics. Dr. Vonderheide has received consulting fees from BMS; research funding from Revolution Medicines; is an inventor on patients relating to cancer cellular immunotherapy, cancer vaccines, and KRAS immune epitopes; and receives royalties from Children’s Hospital Boston for a licensed research-only monoclonal antibody. The remaining authors declare no competing interests.